Cadrenal Therapeutics Shares Rise After Phase 2 Data Shows Fewer Thrombotic Events with CAD-1005
Cadrenal Therapeutics (NASDAQ:CVKD) saw its stock climb 11% after reporting Phase 2 results for CAD-1005 in patients with heparin-induced thrombocytopenia (HIT). The randomized, blinded, placebo-controlled trial in 24 patients showed fewer thrombotic events in the CAD-1005 arm compared with placebo, while the primary endpoint of platelet count reco…